Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,159 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fluarix Clear all
Completed Phase 2 Interventional

Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza

NCT01740063
View directory record Official record
Conditions
Influenza
Interventions
DAS181-F02 formulation, DAS181-F04 formulation, Placebo
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Oct 21, 2026, 1:52 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older

NCT06727058
View directory record Official record
Conditions
Influenza Immunization
Interventions
Pandemic flu H5 mRNA vaccine, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
14
States / cities
La Mesa, California • DeLand, Florida • Lakeland, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 21, 2026, 1:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Self-Administered Nasal Influenza Feasibility Study

NCT01933048
View directory record Official record
Conditions
Influenza
Interventions
FluMist
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 49 Years
Enrollment
1,077 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
San Diego, California • Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 21, 2026, 1:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

NCT00835926
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 21, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults

NCT05945485
View directory record Official record
Conditions
Influenza
Interventions
DCVC H1 HA mRNA vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 21, 2026, 1:52 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

pH1N1 Blinded Challenge Study

NCT07110532
View directory record Official record
Conditions
Influenza
Interventions
A/Arkansas/08/2020 (pH1N1), Sham/Diluent (1X SPG+Arg+Gel)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunology Study of a DNA Trivalent Influenza Vaccine

NCT00375206
View directory record Official record
Conditions
Influenza
Interventions
Trivalent DNA Vaccine (PIA0601) with or without DEI-LT (pPJV2012)
Biological
Lead sponsor
PowderMed
Industry
Eligibility
18 Years to 50 Years
Enrollment
189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
Lenexa, Kansas • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 29, 2007 · Synced Oct 21, 2026, 1:52 AM EDT
Completed Not applicable Interventional Results available

Patient Portal Flu Vaccine Reminders (RCT 6)

NCT06062264
View directory record Official record
Conditions
Influenza, Respiratory Tract Infections
Interventions
Portal-based Video Message, Portal-based Infographic Message
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
6 Months and older
Enrollment
22,233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 21, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults

NCT01014806
View directory record Official record
Conditions
Influenza
Interventions
Influenza VLP Vaccine, TIV
Biological
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
467 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
6
States / cities
Pembroke Pines, Florida • Rochester, Minnesota • Providence, Rhode Island + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 21, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals

NCT03816878
View directory record Official record
Conditions
Influenza
Interventions
H5N1 pISV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 21, 2026, 1:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Performance Feedback in Health Care

NCT04579614
View directory record Official record
Conditions
Influenza
Interventions
The Impact of Performance Feedback and Variable Goal Setting on Flu Vaccination Success Rates of Providers
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
Not listed
Enrollment
595 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 21, 2026, 1:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

NCT01579916
View directory record Official record
Conditions
Influenza
Interventions
Trivalent Influenza Virus Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 21, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children

NCT02649192
View directory record Official record
Conditions
Healthy Participants
Interventions
Influenza virus vaccine, Vitamins A and D, Placebo
Biological · Dietary Supplement · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 8 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 21, 2026, 1:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™

NCT00377611
View directory record Official record
Conditions
Influenza
Interventions
Fluarix™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
3,054 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
9
States / cities
Mobile, Alabama • Delray Beach, Florida • Pembroke Pines, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 21, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024)

NCT00240877
View directory record Official record
Conditions
Influenza
Interventions
AV024, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 20, 2008 · Synced Oct 21, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age

NCT06060457
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Placebo, mRNA-1345, Fluzone HD
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
65 Years and older
Enrollment
1,900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
34
States / cities
Scottsdale, Arizona • Dublin, California • Riverside, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 21, 2026, 1:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Acute Respiratory Illness Surveillance (AcRIS) With Mobile Application in a Low-Interventional Decentralized Study.

NCT04748445
View directory record Official record
Conditions
Healthy
Interventions
SARS-CoV-2/Influenza/RSV RT-PCR
Diagnostic Test
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
9,151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 21, 2026, 1:52 AM EDT
Completed Phase 4 Interventional Results available

High Dose Influenza Vaccine in Nursing Home - Pilot Study

NCT01720277
View directory record Official record
Conditions
Influenza
Interventions
HD Fluzone Vaccine, SD Fluzone Vaccine
Biological
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
65 Years and older
Enrollment
2,957 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Providence, Rhode Island • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 21, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older

NCT07121192
View directory record Official record
Conditions
Influenza, Human
Interventions
Flu mRNA (Formulation A), Flu mRNA (Formulation B), Comparator 1, Comparator 2, Comparator 3
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
22
States / cities
Anniston, Alabama • Fair Oaks, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 21, 2026, 1:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines

NCT02415842
View directory record Official record
Conditions
Immunologic Tests
Interventions
Serum samples
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 64 Years
Enrollment
414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 21, 2026, 1:52 AM EDT
Completed No phase listed Observational

Natural History of Systemic and Nasal Mucosal Immunity After Influenza Vaccination in a Pediatric Population

NCT04963166
View directory record Official record
Conditions
Influenza Immunity
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 17 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 21, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Eldery High Dose TIV 2005

NCT00115531
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years and older
Enrollment
414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
5
States / cities
Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 21, 2026, 1:52 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

H5N1 (Clade 2) Vaccination of Adults and Elderly

NCT00680069
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 99 Years
Enrollment
517 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
8
States / cities
Stanford, California • Iowa City, Iowa • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2016 · Synced Oct 21, 2026, 1:52 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age

NCT00860067
View directory record Official record
Conditions
Healthy or Stable Underlying Chronic Medical Condition
Interventions
Q/LAIV (MEDI3250), FluMist/B/Yamagata, FluMist/B/Victoria
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
18
States / cities
Sacramento, California • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2011 · Synced Oct 21, 2026, 1:52 AM EDT